ONTARIO, CA, August 5, 2010 -- Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to announce they have signed an exclusive license agreement to market and distribute a high potency, highly concentrated vitamin D-3 capsule.
Axxess Pharma, Inc. closed at $0.029 Friday, trading 336,000 shares.
Axxess Pharma, Inc. Signs Exclusive License Agreement to Globally Market and Distribute High Potency Vitamin D-3 to Help Reduce Bone Loss and Joint Pain
About Axxess Pharma, Inc.
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.
Free AXXE small cap stock news and charts available at http://www.stockprofiler.us/Company/AXXE
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
SAN DIEGO, CA, August 9, 2010 -- Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced financial results for the second quarter of 2010.
Cypress Bioscience, Inc. closed at $3.66 Friday, trading 1,126,000 shares.
Cypress Bioscience Announces Second Quarter 2010 Financial Results
About Cypress Bioscience, Inc.
Cypress Bioscience is a pharmaceutical company dedicated to the development of innovative drugs targeting large unmet medical needs for patients suffering from a variety of disorders of the central nervous system. Since 1999, the Company has received multiple FDA approvals, including Prosorba™, a medical device for rheumatoid arthritis, and Savella® (milnacipran HCl), for fibromyalgia. The Company focuses on generating shareholder value by reaching clinical development milestones as quickly and efficiently as possible. Cypress' currently marketed product is Savella. Development-stage assets include CYP-1020 for cognitive impairment in schizophrenia, as well as AVISE-SLE(SM), a lupus diagnostic testing service. AVISE-SLE(SM) is included in the Company's personalized medicine services business, which the Company recently announced it intends to sell or cease operating by the end of the third quarter of 2010. More information on the Company and its products and development assets is available at http://www.cypressbio.com/.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://www.stockprofiler.us/Register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com,
http://www.fastmoneytalk.com, http://www.markettelegraph.com,http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://www.stockprofiler.us/Disclaimer
-------------------------------------------
Keywords: axxe, axxe stock, axxe stock news, axxe stock alerts, axxe company news, axxe small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news updates, small cap stock profile
Posts
